Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease.

ABSTRACT:

Objective

Proton pump inhibitor (PPI) use has been associated with reduced diversity of the gut microbiome and may lead to worse clinical outcomes in inflammatory bowel disease (IBD). We aimed to evaluate whether PPI use affects clinical outcomes in a real-world setting.

Design

Healthcare claims data of adult IBD patients were obtained from the IBM MarketScan Database. Multivariable analysis and propensity score-matched analysis were performed to assess associations between PPI use and new biologic start, and IBD-related hospitalizations and surgeries.

Results

A total of 46,234 IBD patients were identified (6,488 (14%) and 39,746 (86%) patients with and without PPI, respectively). Patients on PPI were more likely to be older, female, and smokers and less likely to be

SUBMITTER: Choden T 

PROVIDER: S-EPMC10124315 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature